Custom Synthesis

Yh25448 View larger

Yh25448

AOB13011

CAS 1903008-80-9

More details

Molarity Calculation Cart®

HOW TO ORDER

$0.00

More info

Novel irreversible EGFR-TKI with potent intracranial activity in EGFR mutant non-small cell lung cancer, showing more potent inhibition of cancer cell growth compared to osimertinib in cancer cells harboring EGFR mutations (L858R/T790 M) with IC50 of 2 nM vs 8 nM and GI50 of 3.6 nM vs 11.8 nM respectively